EMA Authorised: Atectura Breezhaler (indacaterol acetate;mometasone furoate) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Atectura Breezhaler, a combination inhaler containing indacaterol acetate and mometasone furoate, for asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Atectura Breezhaler (indacaterol acetate; mometasone furoate)

Snippet

Status: Authorised. Therapeutic area: Asthma. MAH: Novartis Europharm Limited. Decision date: 20/11/2025